Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 10/20 | 0.58 |
| ▸ | GIPR | P48546 | 7/20 | 0.58 |
| ▸ | GLP1R | P43220 | 1/20 | 0.58 |
| ▸ | GCG | P01275 | 3/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2649311 | 0.88 | GCGR (0.47) | GCGRGIPRGLP1RNPC1RAB9A | |
| SCHEMBL9071343 | 0.82 | GCGR (0.42) | GCGRGIPRGLP1RFFAR1 | |
| SCHEMBL2665548 | 0.82 | GCGR (0.51) | GCGRGIPRGLP1RNPC1RAB9A | |
| SCHEMBL9070862 | 0.79 | GCGR (0.70) | GCGRGIPRGLP1RSMN1; SMN2 | |
| SCHEMBL2651174 | 0.78 | AGER (0.51) | GCGRGCGFFAR1FFAR4 | |
| SCHEMBL2665106 | 0.78 | GCGR (0.55) | GCGRGIPRGLP1R | |
| SCHEMBL2665099 | 0.78 | GCGR (0.52) | GCGRGIPRGLP1RNPC1RAB9A | |
| SCHEMBL2643601 | 0.78 | CA1 (0.61) | NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2653992 | 0.78 | CA1 (0.61) | NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2665170 | 0.77 | GCGR (0.53) | GCGRGIPRGLP1RNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256175-A1 | Novel glucagon antagonists/inverse agonists | LAU JESPER | 2005-11-17 | — | — | US | disclosed |
| US-6881746-B2 | Glucagon antagonists/inverse agonists | NOVO NORDICK A/S (DK) | 2005-04-19 | — | — | US | disclosed |
| EP-1519723-A1 | NOVEL GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2005-04-06 | — | — | EP | disclosed |
| US-20040014789-A1 | Novel glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2004-01-22 | — | — | US | disclosed |
| WO-2004002480-A1 | NOVEL GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
| WO-2004002480-A1 | NOVEL GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
| WO-2002040444-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014789-A1 | Novel glucagon antagonists/inverse agonists | GLP1R, GCGR, GIPR | GCGR 2/4885GIPR 3/4885GLP1R 1/4885 |
| US-20050256175-A1 | Novel glucagon antagonists/inverse agonists | GLP1R, GCGR, GIPR | GCGR 2/4885GIPR 3/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.